{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:33:49Z","timestamp":1787787229512,"version":"build-2784847793"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","award":["175:1298-1304"],"award-info":[{"award-number":["175:1298-1304"]}],"id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.lungcan.2025.108424","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T17:04:57Z","timestamp":1738688697000},"page":"108424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials"],"prefix":"10.1016","volume":"201","author":[{"given":"D. Ross","family":"Camidge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ryun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5033-0006","authenticated-orcid":false,"given":"Ji-Youn","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian J.","family":"Hochmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Delmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentarou","family":"Kudou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1307-1505","authenticated-orcid":false,"given":"Takayuki","family":"Asato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Hupf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9370-5484","authenticated-orcid":false,"given":"Florin","family":"Vranceanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7216-3130","authenticated-orcid":false,"given":"Robert J.","family":"Fram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.lungcan.2025.108424_b0005","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.lungcan.2025.108424_b0010","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"7153","key":"10.1016\/j.lungcan.2025.108424_b0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.lungcan.2025.108424_b0020","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JCO.23.02744","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, Version 2023.3","volume":"42","author":"Jaiyesimi","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108424_b0025","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1021\/acs.jmedchem.6b00306","article-title":"Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase","volume":"59","author":"Huang","year":"2016","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.lungcan.2025.108424_b0030","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-16-0569","article-title":"The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models","volume":"22","author":"Zhang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108424_b0035","unstructured":"U.S. FDA approves Takeda\u2019s ALUNBRIG(R) (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cancer [press release], Accessed 22 March 2024 https:\/\/www.takeda.com\/newsroom\/newsreleases\/2020\/u.s.-fda-approves-takedas-alunbrig-brigatinib-as-a-first-line-treatment-option-for-patients-diagnosed-with-rare-and-serious-form-of-lung-cancer."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108424_b0040","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.20.03570","article-title":"Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) Joint Guideline Update","volume":"39","author":"Hanna","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2025.108424_b0045","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non\u2013small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108424_b0050","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor\u2013naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108424_b0055","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1007\/s10147-022-02232-7","article-title":"Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2J-ALTA study","volume":"12","author":"Sugawara","year":"2022","journal-title":"Int. J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108424_b0060","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1111\/cas.15888","article-title":"Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: final results of the phase 2 J-ALTA trial","volume":"114","author":"Yoshida","year":"2023","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108424_b0065","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jtho.2020.11.004","article-title":"Brigatinib in Japanese patients with ALK-positive NSCLC previously treated with alectinib and other tyrosine kinase inhibitors: outcomes of the phase 2 J-ALTA trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108424_b0070","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108424_b0075","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108424_b0080","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"issue":"29","key":"10.1016\/j.lungcan.2025.108424_b0085","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108424_b0090","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108424_b0095","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jtho.2023.08.010","article-title":"Brigatinib versus alectinib in ALK-positive NSCLC after disease progression on crizotinib: Results of phase 3 ALTA-3 trial","volume":"18","author":"Yang","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108424_b0100","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.jtho.2023.09.109","article-title":"BRIGHTSTAR local consolidative therapy with brigatinib in tyrosine kinase inhibitor-na\u00efve ALK-rearranged metastatic NSCLC [abstract OA22.04]","volume":"18","author":"Elamin","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108424_b0105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4143\/crt.2023.461","article-title":"First-line alectinib vs. brigatinib in advanced non-small cell lung cancer with ALK rearrangement: real-world data","volume":"56","author":"Jeon","year":"2024","journal-title":"Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108424_b0110","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jtho.2018.11.022","article-title":"Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC after treatment with crizotinib","volume":"14","author":"Gemma","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108424_b0115","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/cas.12550","article-title":"Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10708 Japanese patients with non-small-cell lung cancer","volume":"105","author":"Gemma","year":"2014","journal-title":"Cancer Sci."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108424_b0120","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"supplement 3","key":"10.1016\/j.lungcan.2025.108424_b0125","first-page":"22","article-title":"Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) from ALTA-1L [abstract 38P]","volume":"9","author":"Delmonte","year":"2024","journal-title":"ESMO Open"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225000455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225000455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T09:42:30Z","timestamp":1743846150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225000455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":25,"alternative-id":["S0169500225000455"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108424","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108424"}}